Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.34 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.34 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20890576 | 0.83 | GABRA1 (0.32) | GABRA1GABRB2LTB4R | |
| SCHEMBL12322155 | 0.80 | GABRA1 (0.33) | GABRA1GABRB2 | |
| SCHEMBL19879801 | 0.80 | RIPK1 (0.33) | RIPK1 | |
| SCHEMBL20234171 | 0.80 | KLF10 (0.34) | LTB4R | |
| SCHEMBL22940423 | 0.78 | SLC6A2 (0.39) | — | |
| SCHEMBL23597582 | 0.77 | GABRA1 (0.36) | GABRA1GABRB2PDE7A | |
| SCHEMBL18827110 | 0.77 | DPP4 (0.35) | — | |
| SCHEMBL4649171 | 0.73 | — | — | |
| SCHEMBL9032123 | 0.72 | RAB9A (0.31) | — | |
| SCHEMBL6965383 | 0.72 | LTB4R (0.38) | GABRA1GABRB2LTB4RRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210145812-A1 | AMINOAMIDE COMPOUNDS | BIOTHERYX, INC. (US) | 2021-05-20 | — | — | US | disclosed |
| WO-2021022229-A1 | POPULATIONS OF NATURAL KILLER CELLS COMPRISING A CLEAVAGE RESISTANT CD16 | CELULARITY INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| US-10905684-B2 | Aminoamide compounds | BIOTHERYX, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20190106427-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-04-11 | — | — | US | disclosed |
| US-10017522-B2 | Alpha helix mimetics and methods relating thereto | Prism BioLab Co., Ltd. (JP) | 2018-07-10 | — | — | US | disclosed |
| US-20120316156-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS FOR LOWERING SERUM URIC ACID | ANADYS PHARMACEUTICALS, INC. (US) | 2012-12-13 | — | — | US | disclosed |
| US-8329718-B2 | N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CORPORATION (JP) | 2012-04-12 | — | — | US | disclosed |
| US-8012963-B2 | 3,4-dihydro-2H-benzo[1,4]oxazine and thiazine derivatives as CETP inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-09-06 | — | — | US | disclosed |
| US-8012963-B2 | 3,4-dihydro-2H-benzo[1,4]oxazine and thiazine derivatives as CETP inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-09-06 | — | — | US | disclosed |
| US-20100227857-A1 | 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS | KUO GEE-HONG | 2010-09-09 | — | — | US | disclosed |
| US-20100227857-A1 | 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS | KUO GEE-HONG | 2010-09-09 | — | — | US | disclosed |
| US-20100197716-A1 | N-LINKED HETEROCYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-05 | — | — | US | disclosed |
| US-7749995-B2 | 3,4-dihydro-2h-benzo[1,4]oxazine and thiazine derivatives as CETP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-06 | — | — | US | disclosed |
| US-7749995-B2 | 3,4-dihydro-2h-benzo[1,4]oxazine and thiazine derivatives as CETP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-06 | — | — | US | disclosed |
| US-7728008-B2 | N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-01 | — | — | US | disclosed |
| US-7700620-B2 | C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-20 | — | — | US | disclosed |
| US-7550499-B2 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-23 | — | — | US | disclosed |
| US-20070265252-A1 | 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-15 | — | — | US | disclosed |
| US-20070032518-A1 | Compounds and methods of use | AMGEN INC. (US) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227857-A1 | 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS | CETP, MTTP, CES1 | GABRA1 4730/4885GABRB2 4642/4885PDE7A 3035/4885 |
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | GABRA1 2809/4885GABRB2 2851/4885PDE7A 381/4885 |
| US-10905684-B2 | Aminoamide compounds | DNPEP, BCAT2, AADAT | GABRA1 2495/4885GABRB2 1450/4885PDE7A 3242/4885 |
| US-20070265252-A1 | 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS | CETP, MTTP, CES1 | GABRA1 4730/4885GABRB2 4642/4885PDE7A 3035/4885 |
| US-20070032518-A1 | Compounds and methods of use | BAX, BAD, CASP3 | GABRA1 3854/4885GABRB2 3175/4885PDE7A 1072/4885 |
| US-20100197716-A1 | N-LINKED HETEROCYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | P2RY1, P2RY11, P2RY13 | GABRA1 293/4885GABRB2 876/4885PDE7A 321/4885 |
| US-20120316156-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS FOR LOWERING SERUM URIC ACID | THOP1, XDH, DUOX1 | GABRA1 3649/4885GABRB2 4554/4885PDE7A 804/4885 |
| US-10017522-B2 | Alpha helix mimetics and methods relating thereto | PLOD3, COL1A1, THPO | GABRA1 2809/4885GABRB2 2851/4885PDE7A 381/4885 |
| US-20210145812-A1 | AMINOAMIDE COMPOUNDS | DNPEP, BCAT2, AADAT | GABRA1 2495/4885GABRB2 1450/4885PDE7A 3242/4885 |
| US-20190106427-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | GABRA1 4320/4885GABRB2 4035/4885PDE7A 2392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.